Postchemotherapy Immunization Practices for Non-HSCT Pediatric Oncology Patients

Lindy Zhang, Allison M. Martin, Kathy Ruble

Research output: Contribution to journalArticle

Abstract

Pediatric oncology patients treated with antineoplastic therapy have impaired immune systems that lead to loss of protective antibodies. They require reimmunization to protect against vaccine-preventable diseases. There are a paucity of studies on the clinical practice of pediatric oncologists and the available recommendations are heterogenous. This study describes current reimmunization practices among pediatric oncologists. We surveyed the Children's Oncology Group (COG)-identified principle investigators to capture clinical practices among pediatric oncologists within their institutions regarding reimmunization of non-hematopoietic stem cell transplantation patients. The majority of respondents did not routinely assess vaccine-related immune status; those who did most frequently assessed 6 months after cessation of therapies. Methods of assessment included type of therapy received, vaccine titers, and absolute lymphocyte counts. Providers from smaller institutions were more likely to check vaccine titers than those from larger institutions. More than half of the surveyed institutions did not have standardized guidelines available for practitioners. There are variations in reimmunization practices among pediatric oncologists despite available guidelines on recommended schedules. Further research is needed to identify the safest and most cost-effective way to insure immunity to infectious disease after the treatment of childhood cancer.

Original languageEnglish (US)
Pages (from-to)289-293
Number of pages5
JournalJournal of Pediatric Hematology/Oncology
Volume41
Issue number4
DOIs
StatePublished - May 1 2019
Externally publishedYes

Fingerprint

Immunization
Pediatrics
Vaccines
Guidelines
Active Immunotherapy
Lymphocyte Count
Stem Cell Transplantation
Antineoplastic Agents
Communicable Diseases
Immune System
Immunity
Appointments and Schedules
Therapeutics
Research Personnel
Costs and Cost Analysis
Oncologists
Antibodies
Research
Neoplasms

Keywords

  • immunization
  • pediatric oncology
  • postchemotherapy
  • vaccinations

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Postchemotherapy Immunization Practices for Non-HSCT Pediatric Oncology Patients. / Zhang, Lindy; Martin, Allison M.; Ruble, Kathy.

In: Journal of Pediatric Hematology/Oncology, Vol. 41, No. 4, 01.05.2019, p. 289-293.

Research output: Contribution to journalArticle

@article{58dbb2f0090e49ac9bd658e0c5adcd3c,
title = "Postchemotherapy Immunization Practices for Non-HSCT Pediatric Oncology Patients",
abstract = "Pediatric oncology patients treated with antineoplastic therapy have impaired immune systems that lead to loss of protective antibodies. They require reimmunization to protect against vaccine-preventable diseases. There are a paucity of studies on the clinical practice of pediatric oncologists and the available recommendations are heterogenous. This study describes current reimmunization practices among pediatric oncologists. We surveyed the Children's Oncology Group (COG)-identified principle investigators to capture clinical practices among pediatric oncologists within their institutions regarding reimmunization of non-hematopoietic stem cell transplantation patients. The majority of respondents did not routinely assess vaccine-related immune status; those who did most frequently assessed 6 months after cessation of therapies. Methods of assessment included type of therapy received, vaccine titers, and absolute lymphocyte counts. Providers from smaller institutions were more likely to check vaccine titers than those from larger institutions. More than half of the surveyed institutions did not have standardized guidelines available for practitioners. There are variations in reimmunization practices among pediatric oncologists despite available guidelines on recommended schedules. Further research is needed to identify the safest and most cost-effective way to insure immunity to infectious disease after the treatment of childhood cancer.",
keywords = "immunization, pediatric oncology, postchemotherapy, vaccinations",
author = "Lindy Zhang and Martin, {Allison M.} and Kathy Ruble",
year = "2019",
month = "5",
day = "1",
doi = "10.1097/MPH.0000000000001293",
language = "English (US)",
volume = "41",
pages = "289--293",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Postchemotherapy Immunization Practices for Non-HSCT Pediatric Oncology Patients

AU - Zhang, Lindy

AU - Martin, Allison M.

AU - Ruble, Kathy

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Pediatric oncology patients treated with antineoplastic therapy have impaired immune systems that lead to loss of protective antibodies. They require reimmunization to protect against vaccine-preventable diseases. There are a paucity of studies on the clinical practice of pediatric oncologists and the available recommendations are heterogenous. This study describes current reimmunization practices among pediatric oncologists. We surveyed the Children's Oncology Group (COG)-identified principle investigators to capture clinical practices among pediatric oncologists within their institutions regarding reimmunization of non-hematopoietic stem cell transplantation patients. The majority of respondents did not routinely assess vaccine-related immune status; those who did most frequently assessed 6 months after cessation of therapies. Methods of assessment included type of therapy received, vaccine titers, and absolute lymphocyte counts. Providers from smaller institutions were more likely to check vaccine titers than those from larger institutions. More than half of the surveyed institutions did not have standardized guidelines available for practitioners. There are variations in reimmunization practices among pediatric oncologists despite available guidelines on recommended schedules. Further research is needed to identify the safest and most cost-effective way to insure immunity to infectious disease after the treatment of childhood cancer.

AB - Pediatric oncology patients treated with antineoplastic therapy have impaired immune systems that lead to loss of protective antibodies. They require reimmunization to protect against vaccine-preventable diseases. There are a paucity of studies on the clinical practice of pediatric oncologists and the available recommendations are heterogenous. This study describes current reimmunization practices among pediatric oncologists. We surveyed the Children's Oncology Group (COG)-identified principle investigators to capture clinical practices among pediatric oncologists within their institutions regarding reimmunization of non-hematopoietic stem cell transplantation patients. The majority of respondents did not routinely assess vaccine-related immune status; those who did most frequently assessed 6 months after cessation of therapies. Methods of assessment included type of therapy received, vaccine titers, and absolute lymphocyte counts. Providers from smaller institutions were more likely to check vaccine titers than those from larger institutions. More than half of the surveyed institutions did not have standardized guidelines available for practitioners. There are variations in reimmunization practices among pediatric oncologists despite available guidelines on recommended schedules. Further research is needed to identify the safest and most cost-effective way to insure immunity to infectious disease after the treatment of childhood cancer.

KW - immunization

KW - pediatric oncology

KW - postchemotherapy

KW - vaccinations

UR - http://www.scopus.com/inward/record.url?scp=85052811657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052811657&partnerID=8YFLogxK

U2 - 10.1097/MPH.0000000000001293

DO - 10.1097/MPH.0000000000001293

M3 - Article

C2 - 30102648

AN - SCOPUS:85052811657

VL - 41

SP - 289

EP - 293

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 4

ER -